Concepedia

Stephanie K. Ladner

SK

Statistics

Publications

5

Citations

958

H-Index

5

Active since

1997

Affiliations

Translational Therapeutics (United States)(Current)

Stephanie K. Ladner is an author at Translational Therapeutics (United States) specializing in molecular virology, virology, and viral hepatitis.

Publications per year

1997–2000

5

Publications

5

Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication

Stephanie K. Ladner, Michaël Otto, Christopher S. Barker et al. · Antimicrobial Agents and Chemotherapy · 1997 · 635 citations · Full text

Life Sciences, Biology, Molecular Biology +16

Inhibition of Human Hepatitis B Virus Replication by AT-61, a Phenylpropenamide Derivative, Alone and in Combination with (−)β- <scp>l</scp> -2′,3′-Dideoxy-3′-Thiacytidine

Robert W. King, Stephanie K. Ladner, Thomas Miller et al. · Antimicrobial Agents and Chemotherapy · 1998 · 143 citations · Full text

Life Sciences, Biochemistry, Pharmacology +16

Phenylpropenamide derivatives as inhibitors of Hepatitis B virus replication

Robert B. Perni, Samuel C. Conway, Stephanie K. Ladner et al. · Bioorganic & Medicinal Chemistry Letters · 2000 · 81 citations

Pharmacy, Medicinal Chemistry, Pharmacology +12

The hepatitis B virus M539V polymerase variation responsible for 3TC resistance also confers cross-resistance to other nucleoside analogues.

Stephanie K. Ladner, Thomas Miller, Michaël Otto et al. · PubMed · 1998 · 59 citations

Life Sciences, Infectious Diseases, Molecular Biology +17

The M539V Polymerase Variant of Human Hepatitis B Virus Demonstrates Resistance to 2′-Deoxy-3′-Thiacytidine and a Reduced Ability to Synthesize Viral DNA

Stephanie K. Ladner, Thomas Miller, Robert W. King · Antimicrobial Agents and Chemotherapy · 1998 · 40 citations · Full text

Life Sciences, Infectious Diseases, Molecular Biology +17

1–5 of 5